Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily

Pediatric Infectious Disease Journal

Volumn 25, Issue 3, 2006, Pages 208-210

  Bowlware, Karen L ^a,c   McCracken Jr , George H ^b   Lozano Hernandez, Juanita ^b   Ghaffar, Faryal ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Cefdinir; Pharmacokinetics; Tolerability

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFDINIR; CEPHALOSPORIN DERIVATIVE; PENICILLIN G;

ABDOMINAL PAIN; ACUTE OTITIS MEDIA; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INFANT; LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; VOMITING;

ACUTE DISEASE; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; OTITIS MEDIA; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; SOFT TISSUE INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 33644926181     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000202210.22512.88     Document Type: Article

References (7)

1. Jacobs MR. Increasing antibiotics resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters. Pediatr Infect Dis J. 2000;19:S47-S56.
2. Bottenfield GW, Burch DJ, Hedrick JA, Schalen R, Rowinski CA, Davies JT. Safety and tolerability of a new formulation (90 mg/kg/d divided every 12 h) of amoxicillin/clavulanate (Augmentin®) in the empiric treatment of pediatric acute otitis media caused by drug-resistant. Streptococcus pneumoniae. Pediatr Infect Dis J. 1998;17:963-968.
3. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15:255-259.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1198;26:1-12.
5. Omincef® [package insert]. Chicago, IL: Abbott Laboratories; 2004.
6. Arguedas A, Dagan R, Leibovitz E, Hoberman A, Pichichero M, Paris M. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J. 2006;25:211-218.
7. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 29-November 2, 2004, Washington, DC. Washington, DC: American Society for Microbiology; 2004.